AlveoGene的动态

Join us this November for the Sydney International Conference, ‘Advancing Multi-Omics into the Clinic’—Australia, 18th-19th Nov 2024! ??? Over two days, experts from around the globe will discuss the latest innovations in proteomics, genomics, multi-omic data integration within cancer research, drug discovery, regulatory approvals, and commercialisation challenges. Key topics will include:? - Translating cancer signatures into clinical insights? - AI and machine learning for omics? - Multi-omic breakthroughs and drug discovery? - The future of precision medicine Don’t miss out! This will be a great opportunity to hear from top experts in multi-omics, network, and possibly establish new collaborative projects. Register here: https://lnkd.in/dstS8Gyx NSW Health, Thermo Fisher Scientific, Australian Genome Research Facility (AGRF), University of Sydney, Children's Medical Research Institute. #ClinicalResearch, #AdvancingMultiOmicsintotheClinc, #proteomics, #CancerResearch, #MultiOmics, #Drugdiscovery

A unique opportunity for Early and Mid Career Researchers #EMCR to present their work at the #ProCan 2024 Sydney International Conference: Advancing Multi-omics into the Clinic. The abstract deadline is the 9th of September, 2024. This will be a two-day international conference in Sydney where distinguished international speakers will discuss challenges and opportunities for integrating multi-omics into #cancer management regarding biomarker and drug discovery. Bioinformatics and challenges in multi-omic integration will be discussed in a dedicated session #Bioinformatics. There will also be a dedicated session to discuss challenges in regulatory approval #TGA, #HTA, impact on early phase #clinicaltrials, intellectual property (IP) and market access. #cancerresearch, #proteomics, #genomics, #cancer, #oncology, #biomarker, #drugdiscovery. Looking forward to seeing you all: https://lnkd.in/dstS8Gyx Children's Medical Research Institute, University of Sydney, UNSW, The Westmead Institute for Medical Research, Ingham Institute Medical Physics, Children's Cancer Institute, Victorian Clinical Genetics Services (VCGS), University of Adelaide, SAHMRI, Garvan Institute of Medical Research, Omico, Westmead Research Hub

Great news from Race Oncology CEO and I am very proud to say that I have shares in the company. https://raceoncology.com/ I am pleased to share with you results of preclinical work that has found Bisantrene, as a single agent treatment, to be effective against human multiple myeloma in a mouse model and more effective in combination with the standard of care multiple myeloma proteasome inhibitor, carfilzomib. In this study, treatment with Bisantrene was found to significantly slow multiple myeloma disease progression, whereas carfilzomib at the maximum tolerated dosage showed no single-agent activity. However, despite a lack of activity when used alone, carfilzomib, when combined with Bisantrene, was able to slow disease progression more than Bisantrene treatment alone.? It is exciting to see the potential clinical utility of Bisantrene grow. Carfilzomib is a highly active treatment for multiple myeloma, but it comes with very serious cardiotoxicity risks. The potential for using bisantrene to not only better treat multiple myeloma, but also protect patients from the heart damage caused by carfilzomib, is worthy of further investigation. Next steps now include completing mouse models of carfilzomib-induced cardiotoxicity to confirm the cardioprotective properties of bisantrene in vivo, and then exploring options for clinical studies evaluating bisantrene in combination with carfilzomib as a more effective and cardio-safer treatment for patients with multiple myeloma. For further details please visit our Investor Hub?here. Best regards, Dr Daniel Tillett? Chief Executive Officer

Refine your clinical decisions with actionable insights derived from real-world data. Our upcoming webinar on advanced bladder cancer will show you how. Free registrations for HCPs: https://lnkd.in/eQz-8Dwa

Great news from Race Oncology CEO and I am very proud to say that I have shares in the company. https://raceoncology.com/ I am pleased to share with you results of preclinical work that has found Bisantrene, as a single agent treatment, to be effective against human multiple myeloma in a mouse model and more effective in combination with the standard of care multiple myeloma proteasome inhibitor, carfilzomib. In this study, treatment with Bisantrene was found to significantly slow multiple myeloma disease progression, whereas carfilzomib at the maximum tolerated dosage showed no single-agent activity. However, despite a lack of activity when used alone, carfilzomib, when combined with Bisantrene, was able to slow disease progression more than Bisantrene treatment alone.? It is exciting to see the potential clinical utility of Bisantrene grow. Carfilzomib is a highly active treatment for multiple myeloma, but it comes with very serious cardiotoxicity risks. The potential for using bisantrene to not only better treat multiple myeloma, but also protect patients from the heart damage caused by carfilzomib, is worthy of further investigation. Next steps now include completing mouse models of carfilzomib-induced cardiotoxicity to confirm the cardioprotective properties of bisantrene in vivo, and then exploring options for clinical studies evaluating bisantrene in combination with carfilzomib as a more effective and cardio-safer treatment for patients with multiple myeloma. For further details please visit our Investor Hub?here. Best regards, Dr Daniel Tillett? Chief Executive Officer

Friday Focus: Staff in CheCR bring a range of methodological expertise to their research. Today's Friday Focus is on one of these areas: Meta-ethnography. Meta-ethography makes 'a whole into something more than the parts alone imply’ (Noblit & Hare, 1988). Meta-ethnography is a respected, thorough qualitative synthesis method in which researchers select,?analyse and interpret qualitative studies to answer focused questions on a specific topic (e.g. people’s experiences of having and being treated for arthritis) to come up with new insights and conclusions. Prof. Emma France and colleagues from the Centre for Healthcare and Community Research (CHeCR) and elsewhere led the development of international guidance to improve the way researchers report meta-ethnograpies. this guidance is now also available in Spanish and Chinese. Their meta-ethnography website about the guidance development has a wealth of useful information and useful resources: https://emergeproject.org/ A recent meta-ethnography by the team has brought new insights into the area of chronic non cancer pain in children and young people: A meta‐ethnography of how children and young people with chronic non‐cancer pain and their families experience and understand their condition, pain services, and treatments https://lnkd.in/gS2-ruPx #metaethnography #qualitativeresearch #researchmethods #healthresearch University of Stirling

To my colleagues in the brain cancer field, please submit your abstract for the Pediatric SNO meeting using the link above. The deadline is this Friday, January 10th! Please also consider joining the Society for Neuro-Oncology LinkedIn Group to stay abreast of all the exciting developments in research and therapy. Please read on.. Now Accepting Abstracts2025 SNO Pediatric Neuro-Oncology Conference - Call for Abstracts Abstract Deadline: January 10, 2025, 11:59 PM ET The SNO 8th Biennial Pediatric Neuro-Oncology Conference will be held May 15-17, 2025, in San Diego, California at the Hilton San Diego Bayfront. ? Don’t miss the chance to showcase your original research and clinical findings at the 2025 SNO Pediatric Neuro-Oncology Conference! We invite abstract submissions highlighting work in pediatric tumors, including basic science research, translational studies, and clinical trials. Join us in advancing the field of pediatric neuro-oncology! ? TRACK & SUBMISSION CATEGORY DETAILS Atypical Teratoid Rhabdoid Tumor Biological Correlates, Biomarkers Cancer Neuroscience Craniopharyngioma Diffuse Midline Glioma, Diffuse Intrinsic Pontine Glioma Diversity, Equity, and Inclusion Early Phase Clinical Trials/Developmental Therapeutics Embryonal Tumor with Multilayered Rosettes (ETMR), Other Embryonal Tumors, Rare tumors Ependymoma Epidemiology Genomics, Epigenomics, Metabolomics Germ Cell Tumors High Grade Glioma Imaging Immune-, Cell-, Gene-, and Viral-Based Therapies Low Grade Glioma Medulloblastoma Neurofibromatosis and other Cancer Predisposition Syndromes Neuropsychology, Quality of Life, Survivorship Neurosurgery, Drug Delivery Nursing, Social Work, Patient Support Others (not fitting any other category) Palliative Care Pathology, Classification Pediatric Neuro-Oncology in Low/Middle Income Countries Preclinical Models, Drug Discovery Radiation Oncology Tumor Biology, Stem Cells, Models Late Breaking (late breaking submissions must be late phase clinical trials) To learn more and submit your abstract,?click below: https://lnkd.in/e34auFKm

It’s #SarcomaAwareness Month! ?? July is the month to spread awareness about the rare and overlooked type of cancer, Sarcoma, and the actions to take. Sarcoma is the development of cancer groups in supporting tissue, including bone, cartilage, tendons, fat, and muscle. Each year 4,300 people are diagnosed with soft bone tissue sarcoma in England. This month is an influential time to highlight the challenges the resilient sarcoma community endure every day, helping them get one step closer to early and effective treatment. This year the key message is “the importance of early and accurate diagnosis”, #SPAGN is addressing the challenges of how little is known about the reality of diagnosing Sarcoma. Please follow the link below to join the campaign, learn more and share! ?? Here at Fendix, we support any research or positive movements dedicated to helping terminate cancer. Comment below to find out more or make an enquiry at [email protected]. #Sarcoma #Cancer #CureSarcoma?

?? Transforming Clinical Trials in 2025 with GenAI ?? As we step into 2025, AIMED Trial is thrilled to be at the forefront of addressing the growing complexities in clinical trials. We are empowering Pharma, Biotech, Nonprofit Organizations, and CROs to achieve groundbreaking success by overcoming today’s most pressing challenges: ?? Patient Recruitment & Representation ?? Robust Real-World Evidence (RWE) ?? Streamlined Timelines Here’s how we’re making it happen: ?? Synthetic Control Groups & Synthetic Data Generation Our AI-driven tools create external control groups tailored for single-arm trials in rare diseases like oncology, neurology, and cardiovascular conditions. We also generate realistic, privacy-guaranteed synthetic data to address missing datasets and underrepresented patient subgroups. ?? Reliable Real-World Evidence (RWE) Using GenAI and ML-powered applications, we deliver high-quality, regulatory-compliant RWE that overcomes biases, inefficiencies, and data gaps typically seen in traditional observational studies. ?? Computational Models for Clinical Trial Simulation Our state-of-the-art models simulate the human immune system to predict therapeutic effects and adverse reactions, enhancing the design and validation of treatments for cancer, autoimmune disorders, infectious diseases, and more. ?? AIMED Trial bridges the gap between innovation and execution, enabling faster, safer, cost-effective, and more reliable outcomes across all trial phases—from Phase I to post-marketing assessments. ?? Ready to revolutionize your clinical trials? Visit us: www.aimedtrial.com Contact us: [email protected] #ClinicalTrials #AI #GenAI #SyntheticData #RWE #Pharma #Biotech #Innovation #2025